Target intelligence / Profile preview

Malignant or Infected Host Cells

Molecular classification
Other
01

Overview

Malignant or Infected Host Cells refers to a broad category of pathological cell states rather than a specific molecular target like a receptor or enzyme. Malignant cells are characterized by the hallmarks of cancer, including sustained proliferative signaling, evasion of growth suppressors, and the ability to invade and metastasize, often driven by somatic mutations (Hanahan & Weinberg, 2011, Cell). Infected host cells are those that have been compromised by pathogens such as viruses or intracellular bacteria, which utilize the host's metabolic and replicative machinery to propagate the infection (Alberts et al., 2002, Molecular Biology of the Cell). In a therapeutic context, these cells are the intended destination for drugs, but the actual molecular targets are specific proteins or nucleic acids within or on these cells, such as the BCR-ABL kinase in leukemia or viral proteases in HIV (Vanneman & Dranoff, 2012, Nat Rev Cancer). Effective treatment strategies aim to achieve selective toxicity, identifying unique biomarkers or vulnerabilities that distinguish these pathological cells from healthy host tissue to minimize adverse effects.

Other names
Cancer cellsTumor cellsVirally infected cellsPathogen-harboring cellsTransformed cellsHost cells
02

Mechanism of action

Targeted elimination via induction of apoptosis, antibody-dependent cellular cytotoxicity (ADCC), inhibition of intracellular replication, or disruption of oncogenic signaling pathways.

03

Biological functions

Cell proliferationViral replicationImmune evasionApoptosis resistanceMetastasisPathogenesis
04

Disease associations

CancerInfectionInflammation
05

Safety considerations

Off-target toxicity to healthy tissuesCytokine release syndrome (CRS)Development of multi-drug resistance (MDR)MyelosuppressionImmunosuppression
06

Interacting drugs

Rituximab

6 more in the full profile.

07

Biomarkers

Tumor-associated antigens (e.g., CEA, PSA)Viral proteins (e.g., HBsAg)MHC-peptide complexesCirculating tumor DNA (ctDNA)Cell surface receptors (e.g., HER2, CD20)

Beyond the preview

Go deeper on Malignant or Infected Host Cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Malignant or Infected Host Cells.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call